Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITI ...

BEIJING and LUND, Sweden, March 5, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced preliminary encouraging efficacy data for BI-12 ...

BEIJING, Feb. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, proudly announced the administration of the first dose of FOLOTYN® (Pralatrexate Injection) to a patient in China. This remarks a pivotal step in CASI's commitment to addressing critical medical needs in peripheral T-cell lymphoma in China market. FOLOTYN® (Pralatrexate) is a dihydrofolate re ...

www.casipharmaceuticals.com Exhibit 99.1 CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS BEIJING, China (April 26, 2023) CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2022, and provided an update on key highlights for 2022. Wei-Wu He, Ph.D., CASI's Chairman and Chief Exec ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITI ...

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET Company Participants Wei Zhang – Vice President Wei-Wu He – Chairman and Chief Executive Officer Alex Zukiwski – Executive Vice President and Chief Medical Officer Larry Zhang – President Rui Zhang – Vice President-Business Development Conference Call Participants Leland Gershell – Oppenheimer Sean Lee – H.C. Wainwright Operator Good day everyone and welcome to the CASI Pharmaceuticals' Second Quarter 2022 E ...

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Wei-Wu He - Chairman and Chief Executive Officer Wei Zhang - President Larry Zhang - President Alexander Zukiwski - Executive Vice President and Chief Medical Officer James Goldschmidt - Chief Business Development Officer Conference Call Participants Justin Zelin - BTIG Sean Lee - HC Wainwright Trevor Allred - Oppenheimer Operator Good morning everyone and welcome to the CASI Pharmaceutical ...

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Q4 2021 Earnings Conference Call March 28, 2022 8:00 AM ET Company Participants Wei-Wu He - Chairman and Chief Executive Officer Wei Zhang - President Alex Zukiwski - Chief Medical Officer Jim Goldschmidt - Senior Vice President, Business Development Conference Call Participants Leland Gershell - Oppenheimer Sean Lee - H.C. Wainwright Justin Zelin - BTIG Operator Good morning and welcome to the CASI Pharmaceuticals Year End 2021 Conference Call. [Operator Instruction ...

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Q3 2021 Earnings Conference Call November 12, 2021 8:00 AM ET Company Participants Jacob Moshel - IR Wei-Wu He - Chairman & CEO Alexander Zukiwski - Chief Medical Officer Wong Hu - Former COO, General Counsel & Secretary Conference Call Participants Leland Gershell - Oppenheimer Sean Lee - H.C. Wainwright & Co. Justin Zelin - BTIG Operator Hello and welcome to the CASI Pharmaceuticals, announced Third Quarter 2021 Financial Results. [Operator Instructions]. Today's e ...